Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06335394 Active, not recruiting - Clinical trials for Recalcitrant Lower Limb Nonunion

Prospective Study in Adults Evaluating Safety & Efficacy of NVD003 for Bone Reconstruction to Treat Lower Limb Nonunion

Start date: August 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant NVD-003 for bone reconstruction for the treatment of recalcitrant lower limb nonunion.

NCT ID: NCT05987033 Active, not recruiting - Clinical trials for Distal Radius Fractures

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

Start date: August 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.

NCT ID: NCT04777331 Active, not recruiting - Parkinsons Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

PADOVA
Start date: May 5, 2021
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

NCT ID: NCT04027309 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

HOVON 156 AML
Start date: December 20, 2019
Phase: Phase 3
Study type: Interventional

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific inhibitor of mutant FLT3 in comparison to midostaurin and has shown promising clinical activity in AML.

NCT ID: NCT03771859 Active, not recruiting - Melanoma Clinical Trials

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Start date: January 16, 2019
Phase:
Study type: Observational

An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.

NCT ID: NCT03286023 Active, not recruiting - Metastasis Brain Clinical Trials

Stereotactic Radiotherapy for Brain Metastases

CKBrainMeta
Start date: October 2014
Phase:
Study type: Observational

Stereotactic radiotherapy is an innovative treatment enabling to target accurately brain metastases. The aim of this study is to evaluate tumoral response and acute and late toxicity of this treatment.

NCT ID: NCT03284151 Active, not recruiting - Prostate Cancer Clinical Trials

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Start date: January 2015
Phase:
Study type: Observational [Patient Registry]

Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure.

NCT ID: NCT03206385 Active, not recruiting - Pelvis Tumors Clinical Trials

IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume

Boost_Pelvis
Start date: May 31, 2017
Phase:
Study type: Observational [Patient Registry]

The present register has been designed to confirm the hypothesis that while using high quality Intensity Modulated Radiation Techniques (IMRT) and a reduced external beam stereotactic boost component it would be possible to maintain the late severe toxicity rates under the 5 % level in situations where brachytherapy could not be proposed as a boost.

NCT ID: NCT02326337 Active, not recruiting - Diabetic Foot Ulcer Clinical Trials

Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers

TWO2DFU
Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and economical benefits of Cyclical Pressure Topical Wound Oxygen (TWO2) Therapy in the treatment of chronic diabetic foot ulcers. Subjects will wear a standardized off-loading device and use advanced moist wound therapy (AMWT) dressings. Following a 2 week run-in period with the standardized care and after meeting all the eligibility criteria, half the subjects will use the TWO2 device, while the other half will use a sham device.

NCT ID: NCT02141438 Active, not recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

REASSURE
Start date: August 20, 2014
Phase:
Study type: Observational

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.